WallStSmart

Monster Beverage Corp (MNST)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Monster Beverage Corp generates 7223% more annual revenue ($8.79B vs $120.07M). MNST leads profitability with a 23.1% profit margin vs -42.0%. MNST earns a higher WallStSmart Score of 69/100 (B-).

MNST

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 4/9Altman Z: 6.29

PRE

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MNSTUndervalued (+65.3%)

Margin of Safety

+65.3%

Fair Value

$281.82

Current Price

$96.38

$185.44 discount

UndervaluedFair: $281.82Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNST6 strengths · Avg: 9.2/10
Operating MarginProfitability
31.0%10/10

Strong operational efficiency at 31.0%

Altman Z-ScoreHealth
6.2910/10

Safe zone — low bankruptcy risk

Market CapQuality
$93.57B9/10

Large-cap with strong market position

Return on EquityProfitability
23.3%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
23.1%9/10

Keeps 23 of every $100 in revenue as profit

Revenue GrowthGrowth
26.9%8/10

Revenue surging 26.9% year-over-year

PRE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
107.7%10/10

Revenue surging 107.7% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

MNST3 concerns · Avg: 2.7/10
Price/BookValuation
10.8x4/10

Trading at 10.8x book value

PEG RatioValuation
2.742/10

Expensive relative to growth rate

P/E RatioValuation
46.2x2/10

Premium valuation, high expectations priced in

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$310.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.1%2/10

ROE of -22.1% — below average capital efficiency

Free Cash FlowQuality
$-12.33M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MNST

The strongest argument for MNST centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 23.1% and operating margin at 31.0%. Revenue growth of 26.9% demonstrates continued momentum.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 107.7% demonstrates continued momentum.

Bear Case : MNST

The primary concerns for MNST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 46.2x leaves little room for execution misses.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MNST profiles as a growth stock while PRE is a hypergrowth play — different risk/reward profiles.

MNST carries more volatility with a beta of 0.53 — expect wider price swings.

PRE is growing revenue faster at 107.7% — sustainability is the question.

MNST generates stronger free cash flow (584M), providing more financial flexibility.

Bottom Line

MNST scores higher overall (69/100 vs 32/100), backed by strong 23.1% margins and 26.9% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monster Beverage Corp

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.

Visit Website →

Prenetics Global Ltd

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Prenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment opportunity within the dynamic healthcare sector.

Want to dig deeper into these stocks?